EUCTR2017-002163-17-ES进行中（未招募）1 期
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF NICOTINAMIDE IN PATIENTS WITH FRIEDREICHS ATAXIA. - NICOFA
RWTH Aachen University represented by the Rector himself, represented by the Dean of the Medical Faculty0 个研究点目标入组 225 人开始时间: 2020年1月23日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 225
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients must have a molecular genetic diagnosis of Friedreich ataxia with a GAA-repeat expansion on both alleles of the FXN gene and a SARA Score >7 and <28.
- •2. Patients must be =18 and <50 years old and have a weight of at least 50kg.
- •3. Written informed consent prior to study participation
- •4. A female subject is eligible to participate if she is of: Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea or of childbearing potential and agrees to use of appropriate contraceptive measures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 225
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patients with any medical condition or illness that, in the opinion of the investigator would interfere with study compliance and/or impair the patient´s ability to participate or complete the study.
- •2. Any uncontrolled medical or neurological/neurodegenerative condition (other than Friedreich ataxia).
- •3. Clinically significant psychiatric illness (e.g., uncontrolled major depression, schizophrenia, bipolar affective disorder) within 6 months prior to screening.
- •4. Patients with significant clinical dysphagia.
- •5. Hypersensitivity to nicotinamide.
- •6. Patients known to be positive for human immunodeficiency virus (HIV).
- •7. Patients with a significant history of substance abuse (e.g. alcohol or drug abuse) within the previous six months before enrolment.
- •8. Patients with a history of severe allergies to medications.
- •9. Indication of impaired liver function as shown by an abnormal liver function profile at screening (e.g., repeated values of aspartate aminotransferase [AST], alanine aminotransferase [ALT] and bilirubin =3 × the upper limit of normal).
- •10. History of malignancy or carcinoma. The following exceptions may be made after discussion with the Sponsor:
- •Subjects with cancers in remission more than 5 years prior to screening.
- •Subjects with a history of excised or treated basal cell or squamous carcinoma.
- •Subjects with prostate cancer in situ.
- •11. History or evidence of an autoimmune disorder considered clinically significant by the Investigator or requiring chronic use of systemic corticosteroids or other immunosuppressants.
- •12. History of clinically significant cardiac disease (ejection fraction < 40% (normal range 50-70%), cardiac insufficiency defined as New York Heart Association (NYHA) Class >2; clinically significant congenital or acquired valvular disease; symptomatic coronary disease such as prior myocardial infarction or angina, B-type natriuretic peptide (BNP) level increase more than 2 x of the normal age- and gender dependent range; history of unstable arrhythmias, history of atrial fibrillation).
- •13. The subject received an investigational drug within 30 days prior to inclusion into this study.
- •14. Patients taking sodium valproate or any other known histone deacetylase inhibitor.
- •15. Use of vitamin B1 (thiamine), withdrawal should be at least 3 months prior Screening.
- •16. Use of vitamin B3 (nicotinamide), withdrawal should be at least 3 months prior Screening.
- •17. If patients are taking idebenone or coenzyme Q10 (CoQ), this should be stable over the last three months and not changed during the study.
- •18. The subject is unwilling or unable to provide written informed consent and to follow the procedures outlined in the protocol.
- •19. For subjects who will undergo an MRI: Any contraindications to MRI such as, but not limited to cardiac pacemaker, implanted cardiac defibrillator, aneurysm clips, carotid artery vascular clamp, neurostimulator, implanted drug infusion devices, metal fragments or foreign objects in the eyes, skin or body, bone growth/fusion stimulator, cochlear, otologic implant, severe claustrophobia or any condition that would counterindicate an MRI scan.
- •20. Patients participating in another interventional clinical trial, excluding natural history/observational studies, at start of the study or within the last 30 days before study start.
- •21. The subject is mentally or legally incapacitated.
- •22. Pregnant females as determined by positive [serum or urine] hCG test at Screening or prior to dosing.
研究者
相似试验
进行中（未招募）
1 期
A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects with Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.Primary Generalised Tonic Clonic SeizuresMedDRA version: 16.0 Level: LLT Classification code 10034089 Term: Partial seizures NOS System Organ Class: 100000004852EUCTR2010-023263-18-ESPfizer Inc 235 East 42nd Street, New York, NY10017 US219
进行中（未招募）
1 期
A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects with Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.EUCTR2010-023263-18-GBPfizer Inc.219
进行中（未招募）
不适用
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER TRIAL OF PREGABALIN CONTROLLED RELEASE FORMULATION AS ADJUNCTIVE THERAPY IN ADULTS WITH PARTIAL ONSET SEIZURES - PROTOCOL A0081194Adjunctive (add on) therapy for adult subjects with partial onset seizures with or without secondary generalization.MedDRA version: 14.1Level: LLTClassification code 10048674Term: Partial seizures with secondary generalizationSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-019035-35-BGPfizer Inc. 235 East 42nd Street, New York, NY 10017333
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group, multi-centre study to investigate the safety and efficacy of CP-690,550 for induction therapy in subjects with moderate to severe Crohn’s diseaseMedDRA version: 17.0Level: LLTClassification code 10011402Term: Crohn's disease (colon)System Organ Class: 100000004856Crohn's diseaseEUCTR2011-001733-16-NLPfizer Inc.235 East 42nd Street, New York, NY 10017275
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group, multi-centre study to investigate the safety and efficacy of CP-690,550 for induction therapy in subjects with moderate to severe Crohn’s diseaseMedDRA version: 17.1Level: LLTClassification code 10011402Term: Crohn's disease (colon)System Organ Class: 100000004856Crohn's diseaseEUCTR2011-001733-16-CZPfizer Inc.275